Statins and cataract risk: what do we really know?

Statine e rischio di cataratta: cosa sappiamo davvero

Updated and contextualized version of an article originally published on April 28, 2014
The article retains its original focus by presenting it through a scholarly and accessible perspective, supported by verifiable references.

Authors

Dr. A. Conte – Biologist
Roberto Panzironi –Independent researcher

Note editoriali

First publication: April 28, 2014
Last update: April 18, 2026
Version: 2026 narrative revision

Editorial note: This article was originally published in the past and has been updated according to scientific and divulgative criteria. It is for informational purposes only and does not replace the advice of your treating physician.

In brief

Evidence on an association between statins and cataracts is mixed: some observational studies show a modest increase in risk, while randomized trials and meta-analyses do not conclude a clear effect.
The effect may depend on duration and clinical context: results vary for short vs. prolonged use and in populations with different comorbidities.
Plausible biological mechanisms exist (e.g., lens dependence on cholesterol) but plausibility does not prove causality.
For most people at cardiovascular risk, the benefit of statins remains predominant; individual assessment remains fundamental.

Abstract: what does science say?

Discussions and research on a possible link between statin use and cataract development have existed for decades. Some large observational studies report a modest increase in risk associated with statin intake, particularly in analyses with short duration of use or in elderly populations; other observational studies and some clinical trials find no associations or, in some cases, even indicate a reduction in risk. Meta-analyses combining different designs show conflicting results, often explainable by heterogeneity in design, exposure measurement, and confounding. There are also plausible biological mechanisms: the lens synthesizes cholesterol locally, and inhibition of cholesterol biosynthesis can alter its homeostasis; other pathways involve oxidative stress and mitochondrial functions. Overall, the literature does not allow for a robust and generalizable causal relationship to be affirmed; the observed signals require further well-designed studies. Therapeutic decisions must consider the risk/benefit ratio for cardiovascular prevention and the patient's individual situation.

Epidemiological evidence and observational studies

Over the years, numerous observational studies investigating the association between statins and cataracts have been published. Some analyses of registries and clinical databases have found a modest increase in the risk of cataract diagnosis or surgery among statin users compared to non-users [1]. Conversely, other cohort studies have reported no association or even a reduction in the incidence of certain cataract subtypes in subjects treated with statins [4]. Differences between studies depend on the population considered (mean age, presence of diabetes or other comorbidities), the definition of the outcome (clinical diagnosis, lens photograph, or surgical intervention), and the measurement of exposure (prescription vs. actual adherence). Some more recent works on large national cohorts have tested different treatment durations and report variable associations depending on the subgroup examined [5][6]. In summary, observational data provide conflicting signals and are subject to residual confounding: they are useful for generating hypotheses but not for establishing certain causality.

Evidence from clinical trials and meta-analyses

Evidence from randomized controlled trials, which generally provide estimates less subject to confounding than observational studies, has not yet provided consistent proof of an increased risk of cataracts associated with statins. Meta-analyses combining trials and observational studies show heterogeneous results: some observational meta-analyses have reported a small increase in risk, while aggregates including trials do not confirm a significant effect [2][7]. This discrepancy may be attributable to the different designs and the possibility that patients on therapy are more closely monitored and have more frequent visits, leading to differential detection of ocular conditions. Therefore, in the overall balance of evidence, meta-analyses do not allow for a unique and definitive conclusion: observational results require verification in prospective studies with objective outcome measures.

Plausible biological mechanisms

Cholesterol, lens homeostasis, and transparency

The ocular lens has a particular lipid composition and synthesizes cholesterol locally to maintain the integrity and function of the fiber cell membranes. Experimental studies on animal models and molecular research suggest that inhibition of cholesterol biosynthesis in the lens can alter membrane structure, promote alterations in ion transport, and encourage aggregation of lens proteins, phenomena known in cataract formation [10][11]. These data explain the biological plausibility of a possible effect of statins on the lens, but do not demonstrate that clinical use at therapeutic doses causes cataracts in humans.

Pleiotropic effects of statins: oxidative stress and mitochondria

In addition to their role in cholesterol, statins influence metabolic pathways related to mitochondrial function, reactive species production, and inflammatory processes. Some experimental studies show how such alterations could theoretically increase oxidative damage to the lens; other research suggests antioxidant or protective effects depending on the context and duration of use. This set of evidence makes the biological picture complex and not unambiguous: plausible mechanisms exist in both directions [10][11].

Factors modifying the possible risk: dose, duration, and populations

Research results indicate that the observed relationship between statins and cataracts can vary based on relevant characteristics: duration of therapy (short vs. prolonged), drug potency, lipophilicity vs. hydrophilicity of the molecule, and the patient's baseline conditions (age, diabetes, corticosteroid exposure) [1][5]. Some studies have reported an increased risk in the initial phases of treatment or with incomplete adherence, while long-term use has sometimes been neutral or even associated with a reduction in incidence in certain groups [4][5]. This suggests that the time from the start of therapy and the clinical context are crucial in interpreting the results; therefore, it is important not to generalize a single risk value to all clinical conditions.

What it means in practice

For patients and healthcare professionals, the practical message is one of balance and contextualization. Statins are drugs with established benefits in preventing cardiovascular events; signals of a possible modest increase in cataract risk emerge mainly from observational studies and do not constitute definitive proof of a causal link [2][3]. In practical terms: (1) those taking statins for established indications (secondary prevention or high cardiovascular risk) should not discontinue therapy solely based on current evidence regarding cataracts; (2) those undergoing treatment for low-risk primary prevention require an individual discussion of the risk/benefit ratio, as already provided in cardiovascular guidelines; (3) patients with pre-existing risk factors for cataracts (advanced age, prolonged corticosteroid use, diabetes) may consider appropriate ophthalmological surveillance, discussing it with their treating physician. Any therapeutic modification must be decided by the specialist physician on an individual basis.

Key points to remember

The association between statins and cataracts has been reported in observational studies but is not consistently confirmed by randomized trials and combined meta-analyses.
Biological plausibility exists (role of cholesterol in the lens and possible effects on oxidative stress), but plausibility ≠ causality.
The effect, if present, appears modest and variable by treatment duration, population, and outcome definition.
For most patients at cardiovascular risk, the benefit of statins remains prevalent compared to the potential ocular risk.
Do not discontinue therapy without consulting your doctor; individual assessments and ophthalmic surveillance are recommended when appropriate.

Limitations of the evidence

It is essential to distinguish between observed association and proof of causality. Observational studies can be influenced by confounding (for example, the presence of comorbidities that are simultaneously an indication for statins and risk factors for cataracts) and by detection bias (greater contact with healthcare services leads to more frequent diagnoses). Randomized trials are less subject to these biases but are often not designed to evaluate specific ocular outcomes and may have insufficient follow-up to capture slow-onset effects. Other limitations include heterogeneity in cataract definitions, variable measurement of therapy adherence, and differences between statin types. For these reasons, conclusions must be cautious and prioritize prospective studies with objective measures and registries with accurate control of confounders [2][7].

Editorial conclusion

Current scientific literature shows conflicting results on the relationship between statins and cataract risk. While some observational studies report a modest increase in risk, data from clinical trials and meta-analyses do not provide convincing evidence of a consistent harmful effect. Plausible biological mechanisms exist that warrant further research, but at present, the evidence does not require generalized changes in therapeutic recommendations. The decision on the use or discontinuation of statins must remain based on the individual risk/benefit balance for cardiovascular prevention; in case of doubt, it is advisable to consult your treating physician or ophthalmologist for a shared evaluation.

Editorial note

This update was carried out following criteria of transparency, source verification, and institutional divulgative language. The information contained herein does not replace personalized clinical advice. For therapeutic questions, always consult your doctor.